SUPN
Supernus Pharmaceuticals Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Market Cap: 1.7 Billion
Primary Exchange: NASDAQ
Website: https://www.supernus.com
Shares Outstanding: 54.7 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.8929965728654632
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1042 trading days
From: 2018-06-29 To: 2024-03-07
Lowest Point:
Stoke Therapeutics Files Proposed Terms For IPO
via: SeekingAlpha at 2019-06-11 08:24:08:000
Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe genetic diseases with a focus on dominant loss-of-function [haploinsufficient] diseases of … read more...
Stoke Therapeutics Files Proposed Terms For IPO
via: SeekingAlpha at 2019-06-11 08:24:08:000
Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe genetic diseases with a focus on dominant loss-of-function [haploinsufficient] diseases of … read more...
Stoke Therapeutics Files Proposed Terms For IPO
via: SeekingAlpha at 2019-06-11 08:24:08:000
Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe genetic diseases with a focus on dominant loss-of-function [haploinsufficient] diseases of … read more...
How To Find Undervalued Stocks In The Healthcare Sector
via: SeekingAlpha at 2019-06-10 12:10:41:000
The healthcare sector is underperforming the market by a wide margin on a year to date basis. The Healthcare Select Sector ETF ( XLV ) has gained 5.2%, while the SPDR S&P 500 ( SPY ) is up by almost three times that, with a cumulative gain of 15.1% in the same period. Data by YCharts … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|